



GLAND PHARMA LIMITED

October 10, 2022

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as 'Listing Regulations')

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on **Wednesday, 26th October, 2022**, *inter alia*, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended and half year ended September 30, 2022.

Trading Window:

In continuation to our earlier intimation dated September 30, 2022; this is to inform you that the trading window, which was closed from **Saturday, 1st October, 2022** in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on **Saturday, 29th October, 2022**.

Earnings Call:

The Company will hold an Investor/Analyst call on **Wednesday, 26th October, 2022** to discuss the financial results and business outlook. Details of the call will be intimated to the stock exchanges and published on the Company's website (www.glandpharma.com) in due course.

This is for your information and records.

**Yours truly,
For Gland Pharma Limited**

**P Sampath Kumar
Company Secretary and Compliance Officer**